OBJECTIVES: Certolizumab pegol (CZP) is an anti-TNF approved for rheumatoid arthritis (RA) in the UK. Based on 12 week clinical data, NICE guidance recommends CZP as first-line biologic therapy for RA treatment, in conjunction with a Patient Access Scheme (PAS) providing the initial 12 weeks of CZP free of charge to UK NHS. The objective was to assess real-world CZP utilization. METHODS: A retrospective, observational cohort analysis was conducted in four UK Rheumatology clinics. Chart data was collected for biologic-naïve RA patients initiating CZP, followed up to 52 weeks. Reported data included: baseline characteristics, persistence at Weeks 12/24/52, concomitant medication and PAS cost impact. RESULTS: CONCLUSIONS: CZP persistency appeared consistent with data observed in other observational studies of subcutaneous anti-TNFs. Application of the PAS resulted in a substantial reduction in 1-year costs for CZP therapy in comparison to alternatives. PAS-related savings, adjusted for real-world persistency, will also help provide Payers with data to make informed decisions for options to treat RA. Interpretation of data is limited due to retrospective analysis caveats.